In 94 adults with unresectable, symptomatic tenosynovial giant cell tumour, pimicotinib gave a week-25 objective response rate of 54% vs 3% with placebo (difference 51%). Grade 3–4 creatine phosphokinase rise occurred in 13%; mostly mild adverse events.
RCTn = 94
Xu et al. Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trial